NasdaqGS:GHHealthcare
Guardant Health FDA Win Sparks Interest In Liquid Biopsy Valuation Gap
Guardant Health (NasdaqGS:GH) received FDA approval for its Guardant360 Liquid CDx test, described as the most comprehensive blood-based cancer profiling test integrating genomic and epigenomic data.
The approval covers advanced cancer care and expands the test's use as a companion diagnostic across multiple cancer types.
The platform uses AI-enabled multiomic technology to combine genomic and epigenomic insights in a single liquid biopsy.
Guardant Health focuses on liquid biopsy...
